Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Refractory Breast Carcinoma
Interventions: DRUG: Alpha-tocopheryloxyacetic Acid|BIOLOGICAL: Trastuzumab
Sponsor: Veana Therapeutics
Collaborators: University of Washington